Bilateral facial nerve palsy is an uncommon occurrence. We describe a case of bilateral facial nerve palsy secondary to a single cycle of high-dose paclitaxel therapy (825 mg/m 2 ), in a woman with breast cancer. Prior to her high-dose therapy, she had a residual grade 2 peripheral neuropathy following treatment with ten cycles of standard-dose paclitaxel (total dose 3200 mg). The features of the peripheral neuropathy due to standard-dose paclitaxel, which can be both motor and sensory, are well described. Cumulative paclitaxel dose is considered a risk factor for development of the neuropathy. Although facial nerve palsy secondary to paclitaxel is not previously reported, other cranial nerve toxicity has been described. Consistent with reports of the reversibility of paclitaxel-induced peripheral neuropathy, the facial nerve palsies in our patient resolved over 23 months. Ongoing studies of high-dose paclitaxel warrant close attention to its cumulative neurotoxic effects, particularly in patients previously treated with neurotoxic chemotherapy.
Introduction
Paclitaxel is an important chemotherapeutic drug with significant activity in advanced breast cancer [1] . It is derived from the Pacific yew, Taxus brevifolia, and it promotes the formation and stabilization of polymerized microtubules. Paclitaxel dosing and dose schedules are being actively investigated in clinical trials, and studies of high-dose chemotherapy with autologous stem-cell support have incorporated paclitaxel [2] [3] [4] . Neuropathy, predominantly sensory, but also motor and autonomic, is a well-described toxicity of standard-dose paclitaxel [5, 6] . The sensory neuropathy manifests as parasthesia in the hands and feet and perioral parasthesia [5, [7] [8] [9] . It is typically symmetric, and if asymmetric, usually progresses to a symmetric neuropathy with further paclitaxel [5, 7] . Onset of neurologic symptoms may begin within 24-72 hours following paclitaxel administration [5, [7] [8] [9] . The severity is dose-dependent, and is typically mild (National Cancer Institute -Common Toxicity Criteria, grade 1 or 2) with single doses < 200-250 mg/m 2 [5] [6] [7] [8] 10] . Risk factors for neurotoxicity include cumulative paclitaxel dose [5] [6] [7] , prior or concurrent therapy with other neurotoxic chemotherapy agents such as cisplatin [11] [12] , and underlying medical conditions associated with neuropathy (e.g., diabetes mellitus) [5] .
Cases of simultaneous bilateral facial nerve palsy, while uncommon, have been reported as a result of diverse etiologies [13] [14] [15] . Idiopathic Bell's palsy, Guillain-Barre syndrome, infections particularly Lyme disease, and malignancy are amongst the most frequent etiologies. We herein describe a case of simultaneous bilateral facial nerve palsy as a result of high-dose paclitaxel.
Case report
A 62-year-old woman was diagnosed with stage IIB adenocarcinoma of the left breast in 1994. She underwent a modified radical mastectomy, six cycles of adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil, and radiation therapy. Two years later she was found to have bilateral lung metastases. She received paclitaxel at a dose of 200 mg/m 2 every 3 weeks for 10 cycles (total dose 3200 mg), with significant shrinkage of her lung metastases. Her treatment course was notable for the development of a peripheral neuropathy, manifesting as numbness and tingling sensations in a glove and stocking distribution. The patient noted improvement in the neuropathy between cycles and after completion of therapy. Following the final cycle of paclitaxel, examination revealed evidence of a mild sensory neuropathy in the fingers and toes with absent deep tendon reflexes (grade 2). Her cranial nerve examination was normal. Nerve conduction studies (NCS) were consistent with a sensorimotor axonal peripheral neuropathy with superimposed compression of the right median nerve at the wrist (Table 1) . There was no history of diabetes mellitus, alcohol abuse, vitamin deficiency, or thyroid disease.
The patient enrolled in a program of sequential highdose chemotherapy with autologous stem-cell support two months after receiving the last cycle of regular paclitaxel therapy. This high-dose regimen consisted of high-dose paclitaxel, followed by melphalan, followed by cyclophosphamide, thiotepa, and carboplatin (CTCb), each given after hematopoietic recovery [10] . Paclitaxel was given at a dose of 825 mg/m 2 , as a continuous infusion over 24 hours, followed four days later by infusion of peripheral blood stem cells and daily filgrastim. On the day following high-dose paclitaxel, she developed perioral parasthesias, and worsening parasthesias and dysesthesias of the hands and feet. Within one week after high-dose chemotherapy, she had progressive, grade 3 motor and sensory neuropathy with difficulty walking and holding objects in her hands. Her complaints included difficulty eating due to numbness in her mouth and face. Eighteen days following the chemotherapy, she developed simultaneous, bilateral facial nerve palsies. Examination revealed significant, bilateral lower motor neuron weakness in the facial musculature. The remainder of the cranial nerves were unremarkable. There was loss of vibration sense (128 Hz) at both ankles and toes, and proprioception at both great toes was absent. Deep tendon reflexes were absent. Motor function was normal except for bilateral ankle flexor and extensor weakness. Gait and Romberg testing were abnormal. Tests of cerebellar function including fingernose and heel-shin tests were normal. NCS performed 30 days following high-dose paclitaxel and prior to melphalan (Table 1) , demonstrated a moderately severe axonal neuropathy with progression since the prior study. There was evidence of bilateral severe, but partial, facial nerve lesions. Facial nerve latency was borderline with significantly reduced amplitude in the upper and lower branches of both facial nerves. Computed axial tomography of the head, with and without intravenous contrast, revealed no intracranial metastatic lesions. She was started on oral prednisone, 100 mg per day and amitriptyline.
CTCb was administered three months after high-dose paclitaxel without worsening of her bilateral facial nerve palsies. The patient's parasthesias and dysesthesias gradually improved, with normalization of the gait and Romberg testing. The bilateral facial nerve palsies improved slowly, with complete resolution 23 months following the high-dose paclitaxel.
Discussion
Paclitaxel dose, both per-cycle and cumulative, has been implicated as a major risk factor for treatment-related neurotoxicity [5-7, 10, 11] . Following standard-dose paclitaxel (cumulative dose of 3200 mg) which resulted in a residual grade 2 sensory neuropathy, our patient received paclitaxel at a dose of 825 mg/m 2 . She experienced severe grade 3 neuropathy, with bilateral facial nerve palsy. The high dose of paclitaxel in this regimen has been shown to cause both motor and sensory neuropathy, most evident within the first week following paclitaxel administration. NCS from such patients demonstrate decrease in amplitude with normal velocity indicative of an axonal neuropathy [16] .
Moderate, reversible, sensorimotor peripheral neuropathy from high-dose paclitaxel (dose range 500-800 mg/m 2 ) has been confirmed [3] , although Stemmer et al., report only sensory neuropathy from a combination of high-dose paclitaxel, cyclophosphamide, and cisplatin [4] . Dose-escalation correlated with duration of symptoms and delayed improvement. Although no significant correlation was found with dose of drug and severity of the neuropathy, prior neurotoxic chemotherapy did contribute to the severity [3] . Our patient received a considerable cumulative dose of paclitaxel in standard dosing, prior to receiving the high-dose paclitaxel.
Bilateral facial nerve palsy is an uncommon occurrence and is seen less than 1% as often as unilateral facial nerve palsy [17] . This is the first report of bilateral facial nerve palsy as a result of paclitaxel therapy. NCS after paclitaxel confirmed the bilateral facial lesions in our patient, as well as very low amplitudes suggesting a significant degree of axonotmesis. Although facial nerve palsy secondary to paclitaxel has not been previously reported, other cranial nerve toxicity has been described. Capri et al. noted optic nerve disturbances in breast cancer patients secondary to paclitaxel doses of 175 mg/m 2 and 225 mg/m 2 given over three hours every three weeks [18] . Following biweekly dose intensification with vinorelbine (30-36 mg/m 2 ) and paclitaxel (150 mg/m 2 ) for breast cancer, three patients developed vocal cord paralysis or weakness and one patient had cranial nerve XI weakness [19] . Prior experience with high-dose paclitaxel confirms the reversibility of paclitaxel-induced neuropathy, although time to maximal, sometimes complete resolution ranged from 2 to 10 months [2] [3] [4] . In contrast, our patient's facial nerve palsies persisted considerably longer, resolving completely after 23 months.
In high-dose paclitaxel studies, patients should be carefully monitored for unexpected neurologic toxicity, particularly if they have received prior taxanes or other neurotoxic chemotherapy. Strategies to decrease paclitaxel neurotoxicity, such as the use of glutamate deserve further study [20, 21] .
